BioGenCell’s mission is to develop an innovative technology platform that will enable the rapid creation of easy-to-use and cost-effective treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem cells.
Dr. Yael Porat, PHD
Dr. Porat is a specialist in the biotechnology industry, having worked as an innovator, scientist, advisor and director for both industry leaders and pioneering startups.
Prior to founding BioGenCell, Dr. Porat served as CTO for TheraVitae, where she established the R&D and manufacturing departments and was responsible for the research, development and production of the company’s GMP-compliant adult stem cell-based products used for preclinical and clinical studies, as well as for routine treatment of patients.
Previously, Dr. Porat worked for the global R&D division of Teva Pharmaceutical Industries Ltd (Nasdaq: TEVA) as Manager of the Biological Methods Development department where she lead multidisciplinary research teams in development of biological methods supporting pharmaceutical products development. Prior to Teva, she worked for XTL Biopharmaceuticals Ltd (Nasdaq: XTLB) as a senior project manager and member of the project leaders forum in charge of the company’s strategic planning. Dr. Porat, an author of many scientific publications and patents, holds MA and PhD degrees in Immunology from the Sackler School of Medicine, Tel-Aviv University, Israel.